Study M456
Study name | Ali-Sisto T 2018 |
Title | Global arginine bioavailability ratio is decreased in patients with major depressive disorder |
Overall design | The aim of this study was to analyze the serum levels of arginine, citrulline, and ornithine, and calculated global arginine bioavailability ratio (GABR) for a longitudinal sample of major depressive disorder (MDD) patients and for a non-depressed control group. Ninety-nine MDD patients (depression group, n = 99) and 253 non-depressed controls (control group, n = 253), aged 20-71 years, provided background data via questionnaires. Fasting serum samples were analyzed using ultra-performance liquid chromatography coupled to mass spectrometry to determine the serum levels of ornithine, arginine, citrulline, and symmetric and asymmetric dimethylarginine. GABR was calculated as arginine divided by the sum of ornithine plus citrulline. The above measures were compared between: 1) MDD patients and controls, 2) remitted (n = 33) and non-remitted (n = 45) MDD patients, and 3) baseline and follow-up within the remitted and non-remitted groups. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD |
Sample size | 352 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: ACQUITY UPLCMS/MS system with WATERS XEVO-TQ-Striple quadrupole mass spectrometer (Waters Corporation, Milford, MA, USA); |
PMID | |
DOI | |
Citation | Ali-Sisto T, Tolmunen T, Viinamäki H, et al. Global arginine bioavailability ratio is decreased in patients with major depressive disorder. J Affect Disord 2017;229:145-51. |
Metabolite |
